BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 21514606)

  • 1. Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry.
    Pérez-Sola MJ; Torre-Cisneros J; Pérez-Zafrilla B; Carmona L; Descalzo MA; Gómez-Reino JJ;
    Med Clin (Barc); 2011 Nov; 137(12):533-40. PubMed ID: 21514606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy.
    Peña-Sagredo JL; Fariñas MC; Perez-Zafrilla B; Cruz-Valenciano A; Crespo M; Joven-Ibañez B; Riera E; Manero-Ruiz FJ; Chalmeta I; Hernández MV; Rodríguez-Gómez M; Maíz O; López R; Cobo T; Pita J; Carmona L; Gonzalez-Gay MA;
    Clin Exp Rheumatol; 2009; 27(6):920-5. PubMed ID: 20149306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.
    Carmona L; Gómez-Reino JJ; Rodríguez-Valverde V; Montero D; Pascual-Gómez E; Mola EM; Carreño L; Figueroa M;
    Arthritis Rheum; 2005 Jun; 52(6):1766-72. PubMed ID: 15934089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.
    Gómez-Reino JJ; Carmona L; Angel Descalzo M;
    Arthritis Rheum; 2007 Jun; 57(5):756-61. PubMed ID: 17530674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer in patients with rheumatic diseases exposed to TNF antagonists.
    Carmona L; Abasolo L; Descalzo MA; Pérez-Zafrilla B; Sellas A; de Abajo F; Gomez-Reino JJ; ;
    Semin Arthritis Rheum; 2011 Aug; 41(1):71-80. PubMed ID: 21093020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous adverse events during treatment of chronic inflammatory rheumatic conditions with tumor necrosis factor antagonists: study using the Spanish registry of adverse events of biological therapies in rheumatic diseases.
    Hernández MV; Sanmartí R; Cañete JD; Descalzo MA; Alsina M; Carmona L; Gomez-Reino JJ;
    Arthritis Care Res (Hoboken); 2013 Dec; 65(12):2024-31. PubMed ID: 23926075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
    Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M;
    J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Respiratory infections associated with anti-TNFα agents.
    Blanchard E; Truchetet ME; Machelart I; Séneschal J; Raherison-Semjen C
    Med Mal Infect; 2017 Oct; 47(6):375-381. PubMed ID: 28602386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients.
    Salliot C; Gossec L; Ruyssen-Witrand A; Luc M; Duclos M; Guignard S; Dougados M
    Rheumatology (Oxford); 2007 Feb; 46(2):327-34. PubMed ID: 16880188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review.
    Fernández-Espartero MC; Pérez-Zafrilla B; Naranjo A; Esteban C; Ortiz AM; Gómez-Reino JJ; Carmona L;
    Semin Arthritis Rheum; 2011 Feb; 40(4):330-7. PubMed ID: 20864146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infectious complications of biologic agents.
    Martin-Mola E; Balsa A
    Rheum Dis Clin North Am; 2009 Feb; 35(1):183-99. PubMed ID: 19481004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review.
    Cruz Fernández-Espartero M; Pérez-Zafrilla B; Naranjo A; Esteban C; Ortiz AM; Gómez-Reino JJ; Carmona L;
    Semin Arthritis Rheum; 2011 Dec; 41(3):524-33. PubMed ID: 22152489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience.
    Peña-Sagredo JL; Hernández MV; Fernandez-Llanio N; Giménez-Ubeda E; Muñoz-Fernandez S; Ortiz A; Gonzalez-Gay MA; Fariñas MC;
    Clin Exp Rheumatol; 2008; 26(5):854-9. PubMed ID: 19032819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.
    Lee HH; Song IH; Friedrich M; Gauliard A; Detert J; Röwert J; Audring H; Kary S; Burmester GR; Sterry W; Worm M
    Br J Dermatol; 2007 Mar; 156(3):486-91. PubMed ID: 17300238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists.
    García-Doval I; Pérez-Zafrilla B; Descalzo MA; Roselló R; Hernández MV; Gómez-Reino JJ; Carmona L;
    Ann Rheum Dis; 2010 Oct; 69(10):1751-5. PubMed ID: 20551153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.
    Mok CC; Chan KY; Lee KL; Tam LS; Lee KW;
    Int J Rheum Dis; 2014 Dec; 17 Suppl 3():1-8. PubMed ID: 24382315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0.
    Carmona L; Descalzo MA; Ruiz-Montesinos D; Manero-Ruiz FJ; Perez-Pampin E; Gomez-Reino JJ;
    Rheumatology (Oxford); 2011 Jan; 50(1):85-92. PubMed ID: 20601654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Infectious complications of heart transplantation. A prospective study for the first 6 years of a transplantation program].
    Bernabeu-Wittel M; Cañas García-Otero E; Herrero Romero M; Ordóñez Fernández A; Martínez Martínez A; Pérez Bernal J; Cisneros Herreros JM
    Rev Clin Esp; 1999 Aug; 199(8):489-95. PubMed ID: 10522428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serious infections associated with anticytokine therapies in the rheumatic diseases.
    Giles JT; Bathon JM
    J Intensive Care Med; 2004; 19(6):320-34. PubMed ID: 15523118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.